Sutura, Inc.

Sutura, Inc.
Techology Visions Group, Inc.
OTC Bulletin Board : TVGR

August 19, 2005 17:38 ET

Sutura, Inc.: Technology Visions Group, Inc. Name Change Effective August 22, 2005

FOUNTAIN VALLEY, CALIFORNIA--(CCNMatthews - Aug. 19, 2005) - Technology Visions Group, Inc. (OTCBB:TVGR), an applied research and development company, announced today that effective at the opening of trading Monday, August 22, 2005 shares of the Company's common stock will trade under the name Sutura, Inc. and the new ticker symbol will be "SUTU". The new trading symbol is in anticipation of the completion of the merger of Technology Visions Group, Inc. (TVGR), and privately held Fountain Valley, California-based Sutura, Inc.

For more information on the merger refer to the Company's final Preliminary Information Statement dated June 24, 2005 and subsequently filed reports located on the SEC's website (www.sec.gov).

About Sutura, Inc.

Sutura®, Inc. (www.suturaus.com) is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The SuperStitch products provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures. The SuperStitch products are designed for ease of use by physicians, to provide hemostasis. The SuperStitch device is designed for use with or without an access device (e.g., trocar sheath, or cannula), for use during minimally invasive surgical procedures, fluoroscopically guided procedures, or in an open setting. Within the United States the F8 & F6 SuperStitch device has been cleared by the FDA under section 510(k) of the Federal Food, Drug, and Cosmetic Act ("FDC Act") for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch F8 & F6 is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California. "Sutura®" and "SuperStitch®" are registered trademarks of Sutura, Inc.

About Technology Visions Group, Inc.

Technology Visions Group is an applied research and development company of new and innovative technologies, engineering ideas, methods, and processes that hold the potential to become commercially viable products or processes. The Company's current technologies are undergoing certain feasibility studies and/or actual field tests and evaluations in the areas of the treatment and stabilization of buried mixed low-level radioactive waste.

Forward-Looking Information Is Subject to Risk and Uncertainty

Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including consummation of the merger, the acceptance of the SuperStitch® devices by medical providers and the marketplace in general and the success of the proposed marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.

Contact Information

  • Sutura, Inc.
    Barry Forward
    Corporate Communications
    866-676-8386
    www.suturaus.com
    or
    Technology Visions Group, Inc.
    James B. Lahey
    President & CEO
    (714) 427-0388
    (714) 427-0389 (FAX)